Québec Universities at TechConnect Summit 2011


Innovations from Québec universities featured at TechConnect Summit this week in Boston

[Location] – June 14, 2011 - Univalor, MSBi Valorisation, Valeo, SOCPRA and the Office of Sponsored Research of McGill University join their efforts during TechConnect Summit’s expo this week in Boston. These organizations responsible for monetizing inventions developed within their partnering institutions will share a booth, as well as showcase some innovations made across Québec universities in general.

TechConnect is the largest conference in the United States focused on emerging technology commercialization and business for nanotechnology, cleantechnology, and life sciences. The TechConnect program platform focuses on technology matchmaking between F1000 corporations and leading universities from around the world.

This year, one third of the projects submitted by worldwide corporations and universities have been selected by the TechConnect Board. Among them, 11 come from Québec based institutions:

Radio-Radar Fusion System for Intelligent Vehicles and Road Infrastructures (Univalor)

Simple and low cost innovative software-defined data fusion system combining radio and radar functions on a single platform for vehicle-to-vehicle and vehicle-to-infrastructure communications.

High quality plastic optical fiber manufacturing process (Univalor)

New fabrication process of multilayer, based on a modified co-rolling method. This new process suppresses micro voids within the multilayer structure and so reduces losses by a factor of 1000.

Software to develop low cost and highly efficient self-adaptive grippers (Univalor)

Software to design self-adaptive and under-actuated fingers of robotic hands.

Biocidal Additives-Free Polymers (Univalor)

A method of ozone treatment to confer remnant biocide properties to polymers.

Excitelet Imaging technique using dispersive correlation for Structural Health Monitoring (Socpra)

An imaging approach for detection of damages in structures is proposed based on propagation of guided waves into a structure and measurement of reflections induced by damages. The originality relies in the imaging technique that correlates signals measured by an array of sensors with theoretical signals obtained after propagation.

High-speed feedback controller (Valeo)

Very high speed control algorithm that can be tuned for most system (non-linear and unstable systems included). The algorithm can be implemented in a digital signal processor in a cost effective manner. System robustness is maintained or enhanced (no trade-off required).

Novel biomarker signature as a predictor of breast cancer outcome (McGill University)

This 29-gene signature is capable of determining which patients are at risk and require treatment with aggressive therapies (breast cancer) and which patients are not.

New Strategies For Secure, Non-Invasive Transitional for Brain Cancer Treatment (Socpra)

The technology is used to reversibly open the BBB for an easier filtration of the brain cancer treatment essential substances. The invention describes natural peptide derived molecules with improved pharmacological profile and high therapeutic potential. These molecules are able to stimulate B1 human inducible specific receptor (rB1).

Microfluidic Lab-on-Chip Platform for Point of Care Testing (Valeo)

The technology entails a hybrid system using two well accepted molecular diagnostic technologies namely the Lab-On-chip (LOC) and fluorescence. The current focus aims at developing a hand-held beta-type device consisting of a disposable part comprising a monolithically integrated microfluidic device and a spectrometer-on-chip connected to an external display unit.

Light-directed, in situ synthesis of RNA microarrays (McGill)

The IP covers compositions and methods for maskless, light-directed in situ synthesis of RNA microarrays on solid substrates.

Cosmas Therapeutics (McGill University Spin-off)

This spin-off from research led at McGill University in collaboration with three Italian universities and financially backed by MSBiV develops first-in-class family of drug compounds with specificity on MT2 melatonin receptors whose therapeutic indications include insomnia, anxiety and depression